Clostridium difficile infection in 2010: Advances in pathogenesis, diagnosis and management of CDI

Nature Reviews Gastroenterology and Hepatology

Volumn 8, Issue 2, 2011, Pages 67-68

  Gerding, Dale N ^a   Johnson, Stuart ^b  

^a HINES VA HOSPITAL   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; FIDAXOMICIN; GLUTAMATE DEHYDROGENASE; METRONIDAZOLE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CDA1; MONOCLONAL ANTIBODY CDB1; PLACEBO; UNCLASSIFIED DRUG; VANCOMYCIN;

ADD ON THERAPY; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERIUM DETECTION; CLOSTRIDIUM DIFFICILE INFECTION; DIAGNOSTIC TEST; DISEASE SEVERITY; ENDEMIC DISEASE; ENZYME IMMUNOASSAY; FECES CULTURE; GEOGRAPHIC DISTRIBUTION; HUMAN; INTERMETHOD COMPARISON; MORBIDITY; NONHUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RIBOTYPING; SENSITIVITY AND SPECIFICITY; TOXIN ANALYSIS; UNSPECIFIED SIDE EFFECT;

AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL; BACTERIAL PROTEINS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; DNA, BACTERIAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; ENTEROTOXINS; HUMANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 79751493157     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2010.215     Document Type: Review

References (10)

1. Kuehne, S. A. et al. The role of toxin a and toxin B in Clostridium difficile infection. Nature 467, 711-713 (2010).
2. Johnson, S. et al. Fatal pseudomembranous colitis associated with a variant Clostridium difficile strain not detected by toxin a mmunoassay. Ann. Intern. Med. 135, 434-438 (2001). (Pubitemid 32845868)
3. Lyras, D. et al. Toxin B is essential for virulence of Clostridium difficile. Nature 458, 1176-1179 (2009).
4. Lowy, I. et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N. Engl. J. Med. 362, 197-205 (2010).
5. Tenover, F. C et al. impact of strain type on detection of toxigenic Clostridium difficile: comparison of molecular diagnostic and enzyme immunoassay approaches. J. Clin. Microbiol. 48, 3719-3724 (2010).
6. Cohen, S. H. et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of america (SHea) and the nfectious diseases society of america (iDSa). Infect. Control Hosp. Epidemiol. 31, 431-455 (2010).
7. Louie, T., Miller, M., Donskey, C, Mullane, K. & Goldstein, E. J. Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob. Agents Chemother. 53, 223-228 (2009).
8. Tannock, G. W. et al. a new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology 156, 3354-3359 (2010).
9. Gerding, D. N. & Johnson, S. Management of Clostridium difficile infection: thinking inside and outside the box. Clin. Infect. Dis. 51, 1306-1313 (2010).
10. Leav, B. A. et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDi). Vaccine 28, 965-969 (2010).